by PEPID Newsroom | Apr 16, 2019 | Alerts
The American College of Physicians (ACP) issued new guidance statements on breast cancer screening for asymptomatic women of average-risk. This issue follows a thorough review and inclusion of the following existing guidelines and associated evidence: American...
by PEPID Newsroom | Apr 12, 2019 | Alerts
The Democratic Republic of Congo (DRC) is battling to contain the 10th deadly wave of the Ebola virus to sweep the nation. As of April 14, the outbreak has logged 1,198 confirmed infected cases and 768 confirmed fatalities. WHO officials are monitoring the outbreak...
by PEPID Newsroom | Apr 10, 2019 | Alerts
Update to Pulse Alert: Second Highest Record of Measles Since Elimination, 6 Outbreaks within U.S. As of April 4, 2019, 465 individual cases of measles have been confirmed in 19 states. This year officially marks the second highest number of individual cases of...
by PEPID Newsroom | Apr 10, 2019 | Alerts
Sanofi and Cigna are responding to the escalating financial and mortality costs of insulin with affordable patient assistance programs – a first in America’s broken drug pricing system. Beginning June, Sanofi’s Insulins Valyou Savings Program will...
by PEPID Newsroom | Apr 5, 2019 | Alerts
The CDC, several states, the U.S. Department of Agriculture’s Food Safety and Inspection Services, and the U.S. FDA are investigating a multistate outbreak of Shiga Toxin-producing Escherichia coli (E.Coli) O103 infections. There is not yet an identification of a...
by PEPID Newsroom | Apr 4, 2019 | Alerts
Kansas-based EHR vendor Cerner proudly takes the industry lead in adopting HL7’s latest rollout – FHIR Release 4, the normative interoperability standard. The vendor embraced FHIR R4 only 3 months after it was published. “It’s incredibly important that...
by PEPID Newsroom | Apr 4, 2019 | Alerts
The FDA is investigating reports of seizures following the use of e-cigarettes, most involving youth and young adult users. The FDA foresees a potential emerging safety issue with the recent voluntary reports of adverse experiences with tobacco products that...
by PEPID Newsroom | Apr 3, 2019 | Alerts
The US FDA approved Cimzia (certolizumab pegol) injection for treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA), a type of inflammatory arthritis. This is the first fda approved treatment for nr-axSpA. Nr-axSpA causes inflammation in the...
by PEPID Newsroom | Apr 2, 2019 | Alerts
Mayzent (siponimod) The FDA approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Mayzent was shown to be...
by PEPID Newsroom | Apr 1, 2019 | Alerts
Six outbreaks, defined as three or more cases of Measles (Rubeola), are currently ongoing within: New York State, Rockland CountyNew York CityWashingtonCalifornia, Santa Cruz CountyNew JerseyCalifornia, Butte County There have been 387 confirmed individual cases of...
by PEPID Newsroom | Mar 29, 2019 | Alerts
[elfsight_social_share_buttons id=”3″] Jatenzo, (testosterone undecanoate) has been given the FDA greenlight to be used as an oral capsule treatment for men with certain forms of hypogonadism. Jatenzo is the first treatment option for men with certain...
by PEPID Newsroom | Mar 28, 2019 | Alerts
Influenza activity, particularly caused by the A(H3N2) virus, remains elevated across the US. The CDC has released a health advisory, reminding clinicians to keep influenza top of mind when diagnosing patients with respiratory illness. The report contains several...
by PEPID Newsroom | Mar 25, 2019 | Alerts
Multiple states across the U.S. have reported hepatitis A outbreaks among people who use drugs and people experiencing homelessness. Since the initial awareness of the outbreak in 2016, there have been more than 15,000 cases with 57% in need of hospitalizations, and...
by PEPID Newsroom | Mar 21, 2019 | Alerts
The FDA approved the Optimizer Smart system for patients with chronic, moderate-to-severe heart failure who are not suited for treatment with other heart failure devices such as cardiac re-synchronization therapy to restore a normal heartbeat timing pattern. The...
by Anna Tan | Mar 20, 2019 | Alerts
FDA Approves Spravato (esketamine) nasal spray to treat treatment-resistant depression in adults, but is only available at certified doctor’s offices and clinics. Treatment-resistant patients are adults with major depressive disorder, who have tried a minimum of two...
